Anthony Khawaja
The Power List 2017
Anthony Khawaja
Clinical Fellow, Glaucoma Service, Moorfields Eye Hospital, London, UK; Honorary Clinical Research Fellow at the University of Cambridge and University College London, UK
Khawaja completed the prestigious Wellcome Trust PhD program at the University of Cambridge, winning the Nick Day Prize for epidemiology, and he also won the Berkeley Fellowship Award supporting a research program at Harvard Medical School during which time he developed a novel algorithm for analysis of genome-wide data. He established and chaired the Young Ophthalmologists (YO) section of the SOE and has been an active member of the AAO’s YO committee. The YO brand is now growing globally and Anthony has helped establish YO groups for other supranational societies, PAAO, APAO, and MEACO.
An active member of multiple international consortia examining the genetic and environmental epidemiology of eye diseases including the International Glaucoma Genetics Consortium (IGGC), the Consortium for Refractive Error and Myopia (CREAM) and the European Eye Epidemiology (E3) consortium, his primary research passion is discovering the biological processes underlying glaucoma by examining genetic, epidemiological and real-world data. He believes we have a duty to harness the potential knowledge in routinely collected data to better the care of our patients. He has also won several prizes including the Moorfields Research Medal, the Royal College of Ophthalmologists Foulds Trophy and the AAO Secretariat and Achievement awards. In 2016, he was awarded the Moorfields Research Medal. Not much of a physical sportsman, Anthony’s team activities at University were chess during medical school and pool during his PhD.
One nominator said: “Multi-skilled in epidemiology, genetics, statistical methods, imaging and population research, Anthony is a globally recognized and sought after researcher. He is actively collaborating with colleagues in Boston MA, Durham NC, Singapore and Rotterdam, as well as around London, Cambridge, and the wider UK, to make breakthrough advances in eye care. Definitely ‘one to watch’.”
